[PR Newswire] – NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie’s …
Read more on this.
AbbVie Inc. (ABBV), currently valued at $79.37B, finished at $48.31.
Looking at today’s market, ABBV one day range is $49.50 to $50.00 with the price of the stock fluctuating between $35.01 to $54.78 over the last 52 weeks.
ABBV shares are currently priced at 15.39x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 9.59x earnings multiple.
And for those looking to make a return holding the stock, the company pays shareholders $1.60 per share annually in dividends, yielding 3.30%.
Consensus earnings for the current quarter by the 11 sell-side analysts covering the stock is an estimate of $0.82 per share, which would be $0.82 worse than the year-ago quarter and a $0.00 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $3.14 would be a $0.21 setback when compared to the previous year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.10 Billion. If reported, that would be a 2.11% decrease over the year-ago quarter.
More recently, Argus Initiated ABBV at Buy (Aug 12, 2013). Previously, Barclays Initiated ABBV at to Equal Weight.
When considering if the stock is under or overvalued, the average price target is $54.38, which is 12.56% above where the stock opened this morning.
AbbVie Inc (NYSE:ABBV), a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals and much more.
Tag Helper ~ Stock Code: ABBV | Common Company name: AbbVie | Full Company name: AbbVie Inc (NYSE:ABBV) .